FI962073A0 - HIV-proteaasin estäjän prodrug-muotoja - Google Patents

HIV-proteaasin estäjän prodrug-muotoja

Info

Publication number
FI962073A0
FI962073A0 FI962073A FI962073A FI962073A0 FI 962073 A0 FI962073 A0 FI 962073A0 FI 962073 A FI962073 A FI 962073A FI 962073 A FI962073 A FI 962073A FI 962073 A0 FI962073 A0 FI 962073A0
Authority
FI
Finland
Prior art keywords
protease inhibitor
hiv protease
prodrug forms
prodrug
forms
Prior art date
Application number
FI962073A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962073A (fi
Inventor
Jose Alexander
Dilbir Bindra
Bruce D Dorsey
Arnold J Repta
Joseph P Vacca
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI962073A0 publication Critical patent/FI962073A0/fi
Publication of FI962073A publication Critical patent/FI962073A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI962073A 1993-11-18 1996-05-15 HIV-proteaasin estäjän prodrug-muotoja FI962073A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15420493A 1993-11-18 1993-11-18
PCT/US1994/013085 WO1995014016A1 (fr) 1993-11-18 1994-11-14 Bioprecurseurs d'un inhibiteur de la protease du vih

Publications (2)

Publication Number Publication Date
FI962073A0 true FI962073A0 (fi) 1996-05-15
FI962073A FI962073A (fi) 1996-05-15

Family

ID=22550424

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962073A FI962073A (fi) 1993-11-18 1996-05-15 HIV-proteaasin estäjän prodrug-muotoja

Country Status (17)

Country Link
US (1) US5733907A (fr)
EP (1) EP0729467A1 (fr)
JP (1) JPH09505303A (fr)
KR (1) KR960705809A (fr)
CN (1) CN1139432A (fr)
AU (1) AU687128B2 (fr)
CA (1) CA2174649A1 (fr)
CZ (1) CZ140696A3 (fr)
FI (1) FI962073A (fr)
HU (1) HUT76270A (fr)
IL (1) IL111584A0 (fr)
NO (1) NO962000L (fr)
NZ (1) NZ276622A (fr)
PL (1) PL314486A1 (fr)
SK (1) SK61496A3 (fr)
WO (1) WO1995014016A1 (fr)
ZA (1) ZA949127B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (fr) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments de la classe des inhibiteurs d'aspartyle protease
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
OA11573A (en) 1998-06-19 2004-07-01 Vertex Pharma Sulfonamide inhibitors of aspartyl protease.
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
CN1441790A (zh) * 2000-01-28 2003-09-10 罗姆和哈斯公司 增强性质的药物
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7202092B2 (en) * 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2005017106A2 (fr) * 2003-06-17 2005-02-24 California Institute Of Technology Bibliotheques d'enzymes cytochromes p450 optimisees et enzymes p450 optimisees
WO2005010011A2 (fr) * 2003-07-15 2005-02-03 Xenoport, Inc. Synthese de composes acyloxyalkyliques
WO2005019163A2 (fr) * 2003-08-20 2005-03-03 Xenoport, Inc. Prodrogues a base de carbamate d'alkyle acyle, procede de synthese et utilisation
WO2005066122A2 (fr) 2003-12-30 2005-07-21 Xenoport, Inc. Synthese de promedicaments a base de carbamate d'acyloxyalkyle et leurs intermediaires

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541168A (en) * 1895-06-18 Frank e
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0395664A1 (fr) * 1987-10-21 1990-11-07 The Upjohn Company Inhibiteurs de renine contenant une fraction de (1-amino-2-hydroxy-2-heterocyclique) ethyle
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5169952A (en) * 1991-07-02 1992-12-08 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2081970C (fr) * 1991-11-08 1997-07-08 Joseph P. Vacca Utilisation d'agents inhibant la protease du vih pour le traitement du sida
US5463067A (en) * 1993-07-16 1995-10-31 Merck & Co., Inc. Process for making HIV protease inhibitors
DE69426979T2 (de) * 1993-07-16 2001-09-20 Merck & Co., Inc. Verfahren zur herstellung von hiv-proteasehemmern
AU7973994A (en) * 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds

Also Published As

Publication number Publication date
US5733907A (en) 1998-03-31
AU687128B2 (en) 1998-02-19
HUT76270A (en) 1997-07-28
EP0729467A1 (fr) 1996-09-04
HU9601340D0 (en) 1996-07-29
FI962073A (fi) 1996-05-15
SK61496A3 (en) 1996-11-06
JPH09505303A (ja) 1997-05-27
NO962000D0 (no) 1996-05-15
CN1139432A (zh) 1997-01-01
CZ140696A3 (en) 1996-12-11
AU1096095A (en) 1995-06-06
PL314486A1 (en) 1996-09-16
CA2174649A1 (fr) 1995-05-26
ZA949127B (en) 1996-05-17
KR960705809A (ko) 1996-11-08
NO962000L (no) 1996-05-15
NZ276622A (en) 1997-09-22
WO1995014016A1 (fr) 1995-05-26
IL111584A0 (en) 1995-01-24

Similar Documents

Publication Publication Date Title
ATE286025T1 (de) Hiv protease inhibitoren
NO306458B1 (no) DP-IV-serin proteaseinhibitorer
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
PT885887E (pt) Inibidores de sulfonamida de aspartil-protease de hiv
FI893962A (fi) Vid vaord av aids anvaendbara hiv-proteas -inhibitorer.
FI962073A0 (fi) HIV-proteaasin estäjän prodrug-muotoja
PH31249A (en) Inhibitors of hiv protease.
FI943234A0 (fi) Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnos
FI923158A (fi) Hiv-proteas-inhibitorer anvaendbara vid behandling av aids
NO934628D0 (no) Retrovirus-protease-inhibitorer
MX9100121A (es) Inhibidores de proteasas asparticas
DE69312093D1 (de) Prodrug von entzündungshemmenden 3-acyl-2-oxindol-1-carboxamiden
KR950003975U (ko) 열쇠의 표식구
NO920023L (no) Hiv-proteaseinhibitorer
MX9204259A (es) Compuestos inhibidores de proteasa retroviral.
EE9900416A (et) HIV-proteaasi inhibiitorid
SE9501466D0 (sv) Antiviral protease inhibition
DK0717778T3 (da) Höjalkalisk serinprotease
SI0774969T1 (en) Hiv protease inhibitor combination
LT2578B (lt) Saudymo taikinys